複合化療市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、給藥途徑、癌症類型、配銷通路、地區和競爭細分，2020-2030 年預測

2024 年全球複合化療市場價值為 50.7 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 5.08%。複合化療是指根據癌症患者的個人需求制定客製化化療藥物的專門實踐。該過程由具有必要專業知識、設備和基礎設施的藥房或醫療機構來完成。複方化療藥物可以製成各種劑型，例如口服溶液、膠囊、外用藥膏、栓劑和靜脈（IV）製劑。劑型的選擇取決於患者的醫療需求、偏好以及治療計劃的特定要求。複合化療對於有特殊劑量需求或難以吞嚥傳統藥片或膠囊的兒科和老年患者尤其有價值。可以設計複合配方來滿足這些人群的特定需求。

主要市場促進因素

藥物研發的進展

主要市場挑戰

品質控制和安全

主要市場趨勢

對無菌複合的興趣日益濃厚

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球複合化療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類型（細胞毒藥物、荷爾蒙藥物、免疫調節劑、標靶治療藥物、支持性治療藥物）
  • 依給藥途徑（靜脈注射、口服、皮下注射、肌肉注射、鞘內注射）
  • 依癌症類型（乳癌、肺癌、大腸癌、攝護腺癌、白血病、淋巴瘤、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第 6 章：北美複合化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第7章：歐洲複合化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太複合化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲複合化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲複合化療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer SPA
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline SRL

第 16 章：策略建議

第17章調查會社について,免責事項

Global Compounding Chemotherapy Market was valued at USD 5.07 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.08% through 2030. Compounding chemotherapy refers to the specialized practice of preparing customized chemotherapy medications tailored to the individual needs of cancer patients. This process is carried out by compounding pharmacies or healthcare facilities with the necessary expertise, equipment, and infrastructure. Compounded chemotherapy medications can be prepared in various dosage forms, such as oral solutions, capsules, topical creams, suppositories, and intravenous (IV) formulations. The choice of dosage form depends on the patient's medical needs, preferences, and the specific requirements of the treatment plan. Compounding chemotherapy is particularly valuable for pediatric and geriatric patients who may have unique dosing requirements or difficulty swallowing conventional pills or capsules. Compounded formulations can be designed to meet the specific needs of these populations.

Key Market Drivers

Advancements in Drug Development

Targeted therapies have revolutionized cancer treatment by specifically targeting molecules or pathways involved in cancer growth. These therapies are designed to be more selective in attacking cancer cells while sparing healthy ones. Compounded chemotherapy drugs now include a range of targeted agents tailored to individual patient profiles. Immunotherapy drugs, such as immune checkpoint inhibitors, have emerged as a promising approach to cancer treatment. These drugs harness the patient's immune system to recognize and attack cancer cells. Compounding pharmacies prepare these immunotherapies for administration, contributing to their widespread use. The development and approval of biosimilar versions of some chemotherapy agents have increased access to these treatments while reducing costs. Compounding pharmacies may be involved in preparing and supplying biosimilars, ensuring their availability. Nanoparticle-based chemotherapy formulations have been developed to improve drug delivery and enhance the therapeutic index of chemotherapy agents. These nanocarriers can target cancer cells more precisely and reduce side effects. Compounding pharmacies are involved in preparing these advanced formulations. Liposomal encapsulation is a drug delivery technique that involves enclosing chemotherapy drugs in liposomes (tiny fat bubbles). This approach improves drug solubility, extends drug circulation in the body, and enhances drug delivery to tumor sites. Compounded liposomal chemotherapy formulations are increasingly used. Ongoing research efforts continue to identify new chemotherapy agents, combination therapies, and treatment regimens. Compounding pharmacies play a pivotal role in preparing and supplying these innovative drugs for clinical use and research purposes.

Key Market Challenges

Quality Control and Safety

Compounded medications, including chemotherapy drugs, must adhere to strict regulatory guidelines and standards set by government agencies like the U.S. Food and Drug Administration (FDA) in the United States. Compliance with these regulations is critical to ensure the safety and efficacy of compounded drugs. Maintaining consistent quality in compounded chemotherapy drugs is challenging due to variations in raw materials, compounding processes, and equipment. Quality control measures must be in place to ensure that each batch of compounded medication meets established standards. Chemotherapy drugs are typically administered intravenously, which necessitates strict sterility measures during compounding. Contamination can lead to severe infections and adverse patient outcomes. Maintaining sterility is a constant concern. Cross-contamination is a risk when multiple chemotherapy drugs are compounded in the same facility. Stringent cleaning and sanitation procedures are essential to prevent unintended mixing of drugs and contamination. Precise dosing is critical in chemotherapy to achieve the desired therapeutic effect while minimizing side effects. Variability in dosing can lead to treatment failures or toxicity. Ensuring the accuracy of compounded doses is challenging but essential. Some chemotherapy drugs are chemically unstable and can degrade over time. Compounding pharmacies must monitor and manage drug stability to ensure that patients receive medications with the intended potency and efficacy.

Key Market Trends

Rising Interest in Sterile Compounding

Sterile compounding is essential for chemotherapy drugs, which are often administered intravenously or directly into the bloodstream. Ensuring sterility prevents the risk of infections and other complications, which can be life-threatening for cancer patients with compromised immune systems. Many chemotherapy drugs are potent and require precise dosing and administration. Sterile compounding allows for the accurate preparation of these drugs to minimize the risk of dosage errors. Sterile compounding facilitates the customization of chemotherapy regimens based on individual patient profiles, including cancer type, stage, and medical history. This personalized approach aligns with the trend toward precision medicine. The development of advanced drug delivery methods, such as nanoparticle-based formulations and liposomal encapsulation, has increased the demand for sterile compounding. These delivery systems require aseptic preparation. The focus on patient-centered care in oncology emphasizes providing treatments that are safe, effective, and tailored to individual patient needs. Sterile compounding supports this approach by ensuring the highest standards of safety and quality.

Key Market Players

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer S.P.A.
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline S.R.L

Report Scope:

In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounding Chemotherapy Market, By Drug Type:

• Cytotoxic Drugs
• Hormonal Agents
• Immunomodulatory Agents
• Targeted Therapies
• Supportive Care Drugs

Compounding Chemotherapy Market, By Route of Administration:

• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• Intrathecal

Compounding Chemotherapy Market, By Cancer Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma

Compounding Chemotherapy Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Compounding Chemotherapy Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.

Available Customizations:

Global Compounding Chemotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Compounding Chemotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs)
  • 5.2.2. By Route of Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
  • 5.2.3. By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Compounding Chemotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Cancer Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Compounding Chemotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Mexico Compounding Chemotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Canada Compounding Chemotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Compounding Chemotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Cancer Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Compounding Chemotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Compounding Chemotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Compounding Chemotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Compounding Chemotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Compounding Chemotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Compounding Chemotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Cancer Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Compounding Chemotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Compounding Chemotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. South Korea Compounding Chemotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Japan Compounding Chemotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Cancer Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Compounding Chemotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Cancer Type
      • 8.3.5.2.4. By Distribution Channel

9. South America Compounding Chemotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Cancer Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Compounding Chemotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Compounding Chemotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Compounding Chemotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Compounding Chemotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Cancer Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Compounding Chemotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Compounding Chemotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Compounding Chemotherapy market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Baxter International Inc.
  • 15.2.1. Business Overview
  • 15.2.2. Company Snapshot
  • 15.2.3. Products & Services
  • 15.2.4. Financials (In case of listed companies)
  • 15.2.5. Recent Developments
  • 15.2.6. SWOT Analysis
• 15.3. Grifols SA
  • 15.3.1. Business Overview
  • 15.3.2. Company Snapshot
  • 15.3.3. Products & Services
  • 15.3.4. Financials (In case of listed companies)
  • 15.3.5. Recent Developments
  • 15.3.6. SWOT Analysis
• 15.4. Comecer S.P.A.
  • 15.4.1. Business Overview
  • 15.4.2. Company Snapshot
  • 15.4.3. Products & Services
  • 15.4.4. Financials (In case of listed companies)
  • 15.4.5. Recent Developments
  • 15.4.6. SWOT Analysis
• 15.5. Arxium Inc.
  • 15.5.1. Business Overview
  • 15.5.2. Company Snapshot
  • 15.5.3. Products & Services
  • 15.5.4. Financials (In case of listed companies)
  • 15.5.5. Recent Developments
  • 15.5.6. SWOT Analysis
• 15.6. Dedalus Group
  • 15.6.1. Business Overview
  • 15.6.2. Company Snapshot
  • 15.6.3. Products & Services
  • 15.6.4. Financials (In case of listed companies)
  • 15.6.5. Recent Developments
  • 15.6.6. SWOT Analysis
• 15.7. B. Braun Melsungen AG
  • 15.7.1. Business Overview
  • 15.7.2. Company Snapshot
  • 15.7.3. Products & Services
  • 15.7.4. Financials (In case of listed companies)
  • 15.7.5. Recent Developments
  • 15.7.6. SWOT Analysis
• 15.8. Omnicell Technologies Inc.
  • 15.8.1. Business Overview
  • 15.8.2. Company Snapshot
  • 15.8.3. Products & Services
  • 15.8.4. Financials (In case of listed companies)
  • 15.8.5. Recent Developments
  • 15.8.6. SWOT Analysis
• 15.9. The Metrix Company
  • 15.9.1. Business Overview
  • 15.9.2. Company Snapshot
  • 15.9.3. Products & Services
  • 15.9.4. Financials (In case of listed companies)
  • 15.9.5. Recent Developments
  • 15.9.6. SWOT Analysis
• 15.10.Sterline S.R.L.
  • 15.10.1. Business Overview
  • 15.10.2. Company Snapshot
  • 15.10.3. Products & Services
  • 15.10.4. Financials (In case of listed companies)
  • 15.10.5. Recent Developments
  • 15.10.6. SWOT Analysis

16. Strategic Recommendations

17. About Us & Disclaimer